Literature DB >> 17720721

Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus.

A M Bertoli1, L M Vilá, J D Reveille, G S Alarcón.   

Abstract

OBJECTIVE: To determine the features associated with acute onset systemic lupus erythaematosus (SLE).
METHODS: A total of 631 SLE patients from LUMINA (for "lupus in minority populations: nature vs nurture"), a multiethnic (Hispanics, African-Americans and Caucasians) cohort, were studied. Acute disease onset was defined as the accrual of > or = 4 American College of Rheumatology (ACR) criteria for the classification of SLE in < or = 4 weeks. Socioeconomic demographic features, clinical manifestations, disease activity, damage accrual, mortality, autoantibodies, HLA class II and FCGR alleles, behavioural/psychological variables were compared between patients with acute and insidious disease onset by univariable (chi(2) and Student t test) and multivariable (stepwise logistic regression) analyses.
RESULTS: A total of 94 (15%) patients had acute disease onset. In the multivariable analysis, patients with acute onset lupus had more renal involvement (odds ratio (OR) = 1.845, 95% CI 1.076-3.162; p = 0.026) and higher disease activity (OR = 1.057, 95% CI 1.005-1.112; p = 0.030). By contrast, age (OR = 0.976, 95% CI 0.956-0.997; p = 0.025), education (OR = 0.901, 95% CI 0.827-0.983, p = 0.019), health insurance (OR = 0.423, 95% CI 0.249-0.718; p = 0.001) and skin involvement (OR = 0.346, 95% CI 0.142-0.843; p = 0.019) were negatively associated with acute onset lupus. No differences were found regarding the serological, genetic and behavioural/psychological features; this was also the case for damage accrual and mortality.
CONCLUSIONS: Patients with acute onset lupus seem to be younger, have a lower socio-economic status and display more severe disease in terms of clinical manifestations and disease activity. However, intermediate (damage) and long-term (mortality) outcomes appear not to be influenced by the type of disease onset in SLE.

Entities:  

Mesh:

Year:  2007        PMID: 17720721      PMCID: PMC2735400          DOI: 10.1136/ard.2007.076059

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

2.  Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody.

Authors:  R G Hamilton; J B Harley; W B Bias; M Roebber; M Reichlin; M C Hochberg; F C Arnett
Journal:  Arthritis Rheum       Date:  1988-04

3.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

4.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

Review 5.  Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus.

Authors:  Andrea T Borchers; Carl L Keen; Yehuda Shoenfeld; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2004-08       Impact factor: 9.754

6.  Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity.

Authors:  Graciela S Alarcón; Gerald McGwin; Martha L Sanchez; Holly M Bastian; Barri J Fessler; Alan W Friedman; Bruce A Baethge; Jeffrey Roseman; John D Reveille
Journal:  Arthritis Rheum       Date:  2004-02-15

7.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

Authors:  M H Liang; S A Socher; M G Larson; P H Schur
Journal:  Arthritis Rheum       Date:  1989-09

8.  Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitudes Index.

Authors:  E W Engle; L F Callahan; T Pincus; M C Hochberg
Journal:  Arthritis Rheum       Date:  1990-02

9.  Dimensions of illness behaviour as measured by the Illness Behaviour Questionnaire: a replication study.

Authors:  I Pilowsky
Journal:  J Psychosom Res       Date:  1993-01       Impact factor: 3.006

10.  Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.

Authors:  L M Vilá; G S Alarcón; G McGwin; A W Friedman; B A Baethge; H M Bastian; B J Fessler; J D Reveille
Journal:  Rheumatology (Oxford)       Date:  2003-11-17       Impact factor: 7.580

View more
  4 in total

1.  Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.

Authors:  Tamar B Rubinstein; Wenzhu B Mowrey; Norman T Ilowite; Dawn M Wahezi
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-07       Impact factor: 4.794

Review 2.  Disparities in lupus care and outcomes.

Authors:  Kristina L Demas; Karen H Costenbader
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

Review 3.  P-glycoprotein and drug resistance in systemic autoimmune diseases.

Authors:  Andrea Picchianti-Diamanti; Maria Manuela Rosado; Marco Scarsella; Bruno Laganà; Raffaele D'Amelio
Journal:  Int J Mol Sci       Date:  2014-03-20       Impact factor: 5.923

4.  Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.

Authors:  Maria Lucia Specchia; Chiara de Waure; Maria Rosaria Gualano; Andrea Doria; Giuseppe Turchetti; Lara Pippo; Francesco Di Nardo; Silvio Capizzi; Chiara Cadeddu; Flavia Kheiraoui; Luca Iaccarino; Francesca Pierotti; Ilaria Palla; Maria Assunta Veneziano; Daniela Gliubizzi; Antonella Sferrazza; Nicola Nicolotti; Rolando Porcasi; Giuseppe La Torre; Maria Luisa Di Pietro; Walter Ricciardi
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.